Review: Vaccine-induced immune thrombotic thrombocytopenia.
16 Nov, 2021 | 08:46h | UTCVaccine-induced immune thrombotic thrombocytopenia – The Lancet Haematology
Related:
Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.
Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.
Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)
Commentary on Twitter
NEW Viewpoint by @Erik_Klok_MD, @MPaiMD, Menno Huisman & @ProfMakris discussing the epidemiology, pathophysiology, and optimal diagnostic and therapeutic management of vaccine-induced immune thrombotic thrombocytopenia #VITT #COVID19Vaccine https://t.co/FI4NynwzEn pic.twitter.com/9PbjaioA2T
— The Lancet Haematology (@TheLancetHaem) November 12, 2021